FDA Recalls Lisinopril and Hydrochlorothiazide Tablets Due to Temperature Storage Deviations
Cardinal Healthcare is recalling Lisinopril and Hydrochlorothiazide Tablets (10mg/12.5mg) manufactured by Lupin Limited because products were exposed to temperatures outside the labeled storage conditions. Affected batches are Q101699 and Q101981 distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II drug recall involving a CGMP deviation where product stability may be compromised due to improper storage temperatures. No illnesses or injuries have been reported, making this a risk-of-harm product where injury has not yet been reported, consistent with a High (3) severity classification.
Plain-English summary
Cardinal Healthcare is recalling Lisinopril and Hydrochlorothiazide Tablets USP (10mg/12.5mg) manufactured by Lupin Limited. The product batches Q101699 and Q101981 were exposed to temperatures outside of the labeled storage conditions, which is a current good manufacturing practice (CGMP) deviation.
The recalled product is a prescription combination medication used to treat high blood pressure. The affected NDC is 68180-518-01 and the product was distributed nationwide.
Temperature exposure outside labeled storage conditions can potentially affect medication stability and efficacy. Patients who have received this medication should contact their healthcare provider or pharmacist if they have any concerns or questions about their supply.
The recalled product
- Product
- LISINOPRIL AND HYDROCHLOROTHIAZIDE (LISINOPRIL AND HYDROCHLOROTHIAZIDE)
- Brand
- LISINOPRIL AND HYDROCHLOROTHIAZIDE
- Manufacturer
- CARDINAL HEALTHCARE
- Category
- Drug
- Affected units
- 2
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Batch Q101699
- Q101981
UPCs (3)
- 0368180519010
- 0368180518013
- 0368180520016
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 42 recalled by CARDINAL HEALTHCARE under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 42 products in this recall →Related recalls
Same brand · LISINOPRIL AND HYDROCHLOROTHIAZIDE
- HighLisinopril and hydrochlorothiazide bottle contained a foreign antiretroviral tablet
FDA (Drugs) · 2025-07-23
- ModerateLupin Recalls Lisinopril and Hydrochlorothiazide Tablets Due to Foreign Substance
FDA (Drugs) · 2019-08-21
- HighLupin Recalls Lisinopril and Hydrochlorothiazide Tablets Due to Foreign Object
FDA (Drugs) · 2019-07-31
- ModerateLupin Recalls Lisinopril and Hydrochlorothiazide Tablets Due to CGMP Deviations
FDA (Drugs) · 2016-07-06
Same manufacturer · CARDINAL HEALTHCARE
See all →- HighAlbuterol Sulfate Inhaler Recalled Due to Temperature Storage Deviation
FDA (Drugs) · 2024-01-03
- ModerateMeloxicam 15 mg tablets recalled for exposure to improper storage temperatures
FDA (Drugs) · 2024-01-03
- HighPredniSONE Tablets Recalled for Temperature Storage Deviation
FDA (Drugs) · 2024-01-03
- HighLow-dose aspirin recall due to improper storage temperature conditions
FDA (Drugs) · 2024-01-03
- HighBumetanide Tablets Recalled for Exposure to Improper Storage Temperatures
FDA (Drugs) · 2024-01-03
Same hazard · temperature excursion
See all →- ModerateCyclophosphamide injection vials recalled after a transportation temperature excursion
FDA (Drugs) · 2025-09-24
- ModerateXolair 75 mg syringes exposed to temperatures outside labeled storage requirements
FDA (Drugs) · 2025-08-13
- ModerateRecombinate antihemophilic factor vials exposed to temperatures outside labeled storage
FDA (Drugs) · 2025-08-13
- ModerateXolair auto-injectors exposed to temperatures outside labeled storage requirements
FDA (Drugs) · 2025-08-13
- ModerateProlia prefilled syringes recalled after potential temperature excursions during transit delays
FDA (Drugs) · 2025-07-30